Heska Corporation (HSKA): Price and Financial Metrics


Heska Corporation (HSKA): $67.00

0.58 (+0.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HSKA POWR Grades

  • Growth is the dimension where HSKA ranks best; there it ranks ahead of 96.68% of US stocks.
  • HSKA's strongest trending metric is Quality; it's been moving up over the last 177 days.
  • HSKA's current lowest rank is in the Sentiment metric (where it is better than 4.93% of US stocks).

HSKA Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.4 for HESKA CORP; that's greater than it is for just 22.43% of US stocks.
  • Over the past twelve months, HSKA has reported earnings growth of 573.13%, putting it ahead of 96.96% of US stocks in our set.
  • In terms of volatility of its share price, HSKA is more volatile than 77.79% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to HESKA CORP, a group of peers worth examining would be KTOS, KRMD, FNGR, CXM, and VCYT.
  • HSKA's SEC filings can be seen here. And to visit HESKA CORP's official web site, go to www.heska.com.

HSKA Valuation Summary

  • In comparison to the median Healthcare stock, HSKA's price/earnings ratio is 286.32% lower, now standing at -43.6.
  • HSKA's price/earnings ratio has moved down 42.4 over the prior 243 months.

Below are key valuation metrics over time for HSKA.

Stock Date P/S P/B P/E EV/EBIT
HSKA 2022-12-02 2.7 1.7 -43.6 -36.0
HSKA 2022-12-01 2.8 1.8 -44.1 -36.4
HSKA 2022-11-30 2.7 1.7 -42.9 -35.4
HSKA 2022-11-29 2.5 1.6 -40.2 -33.0
HSKA 2022-11-28 2.5 1.6 -40.4 -33.1
HSKA 2022-11-25 2.6 1.6 -41.5 -34.1

HSKA Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -172.01%.
  • Its 2 year cash and equivalents growth rate is now at -9.67%.
  • The 5 year cash and equivalents growth rate now stands at 1671.77%.
Over the past 37 months, HSKA's revenue has gone up $136,078,000.

The table below shows HSKA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 259.037 -17.676 -16.222
2022-06-30 257.785 -17.521 -17.684
2022-03-31 258.036 -12.755 -13.005
2021-12-31 253.739 6.247 -1.148
2021-09-30 249.993 12.717 1.871
2021-06-30 246.389 19.593 -1.45

HSKA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HSKA has a Quality Grade of C, ranking ahead of 66.81% of graded US stocks.
  • HSKA's asset turnover comes in at 0.51 -- ranking 81st of 682 Pharmaceutical Products stocks.
  • NEOG, CLVS, and FLXN are the stocks whose asset turnover ratios are most correlated with HSKA.

The table below shows HSKA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.510 0.417 0.001
2021-03-31 0.525 0.411 -0.016
2020-12-31 0.522 0.412 -0.049
2020-09-30 0.492 0.423 -0.050
2020-06-30 0.473 0.430 -0.055
2020-03-31 0.504 0.447 -0.033

HSKA Price Target

For more insight on analysts targets of HSKA, see our HSKA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $282.50 Average Broker Recommendation 1.6 (Moderate Buy)

HSKA Stock Price Chart Interactive Chart >

Price chart for HSKA

HSKA Price/Volume Stats

Current price $67.00 52-week high $189.37
Prev. close $66.42 52-week low $58.00
Day low $63.00 Volume 2,222
Day high $67.00 Avg. volume 84,619
50-day MA $69.31 Dividend yield N/A
200-day MA $97.37 Market Cap 725.34M

Heska Corporation (HSKA) Company Bio


Heska Corporation sells advanced veterinary diagnostic and other specialty veterinary products, including blood testing instruments and supplies, digital imaging products, software and services, and single-use products and services such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. The company was founded in 1988 and is based in Loveland, Colorado.


HSKA Latest News Stream


Event/Time News Detail
Loading, please wait...

HSKA Latest Social Stream


Loading social stream, please wait...

View Full HSKA Social Stream

Latest HSKA News From Around the Web

Below are the latest news stories about HESKA CORP that investors may wish to consider to help them evaluate HSKA as an investment opportunity.

Wall Street Analysts Are Neutral on Top Healthcare Picks

Analysts fell to the sidelines weighing in on Heska (HSKA – Research Report), NanoString Tech (NSTG – Research Report) and Revance Therapeutics (RVNC – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Heska (HSKA) In a report released today, Erin Wright from Morgan Stanley maintained a Hold rating on Heska, with a price target of $135.00. The company's shares closed last Wednesday at $64.61, close to its 52-week low of $58.00. According to TipRanks.

Brian Anderson on TipRanks | November 9, 2022

Will Heska Corporation (HSKA) Overcome the Current Challenges?

Alger Capital, an investment management company, released its “Alger Small Cap Focus Fund” third quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the fund outperformed the Russell 2000 Growth Index. Consumer discretionary and industrial sectors contributed to the fund’s relative performance in the quarter, while healthcare and energy […]

Yahoo | November 8, 2022

Heska (HSKA) Q3 Earnings and Revenues Lag Estimates

Heska (HSKA) delivered earnings and revenue surprises of -8.89% and 11.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 8, 2022

Heska Corporation Reports Third Quarter 2022 Results

Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, reported financial results in two segments (North America and International) for its third quarter ended September 30, 2022. In this release, Point of Care is "POC", Pharmaceuticals, Vaccines and Diagnostics is "PVD", Other Vaccines and Pharmaceuticals is "OVP", and basis points is "bps".

Yahoo | November 8, 2022

Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its Nu.Q® Vet Cancer Screening Test across the U.S. and the forthcoming launch in Europe by Heska Corporation (NASDAQ: HSKA) ("Heska"), a leading global provider of advanced veterinary diagnostics, through Heska's veterinary diagnostic laboratories.

Yahoo | November 3, 2022

Read More 'HSKA' Stories Here

HSKA Price Returns

1-mo 4.77%
3-mo -23.88%
6-mo -28.89%
1-year -58.97%
3-year -30.01%
5-year -18.27%
YTD -63.29%
2021 25.29%
2020 51.81%
2019 11.43%
2018 7.34%
2017 12.03%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7877 seconds.